188 related articles for article (PubMed ID: 28285839)
1. Clinical assessment of coiled fiducial markers as internal surrogates for hepatocellular carcinomas during gated stereotactic body radiotherapy with a real-time tumor-tracking system.
Hanazawa H; Takahashi S; Shiinoki T; Park SC; Yuasa Y; Koike M; Kawamura S; Shibuya K
Radiother Oncol; 2017 Apr; 123(1):43-48. PubMed ID: 28285839
[TBL] [Abstract][Full Text] [Related]
2. Intercepting radiotherapy using a real-time tumor-tracking radiotherapy system for highly selected patients with hepatocellular carcinoma unresectable with other modalities.
Taguchi H; Sakuhara Y; Hige S; Kitamura K; Osaka Y; Abo D; Uchida D; Sawada A; Kamiyama T; Shimizu T; Shirato H; Miyasaka K
Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):376-80. PubMed ID: 17869660
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes of stage I and IIA non-small cell lung cancer patients treated with stereotactic body radiotherapy using a real-time tumor-tracking radiotherapy system.
Katoh N; Soda I; Tamamura H; Takahashi S; Uchinami Y; Ishiyama H; Ota K; Inoue T; Onimaru R; Shibuya K; Hayakawa K; Shirato H
Radiat Oncol; 2017 Jan; 12(1):3. PubMed ID: 28057036
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic outcome and related predictors of stereotactic body radiotherapy for small liver-confined HCC: a systematic review and meta-analysis of observational studies.
Long Y; Liang Y; Li S; Guo J; Wang Y; Luo Y; Wu Y
Radiat Oncol; 2021 Apr; 16(1):68. PubMed ID: 33832536
[TBL] [Abstract][Full Text] [Related]
5. Stereotactic body radiotherapy in hepatocellular carcinoma: patient selection and predictors of outcome and toxicity.
Loi M; Comito T; Franzese C; Dominici L; Lo Faro L; Clerici E; Franceschini D; Mancosu P; Reggiori G; Gallo P; Badalamenti M; Scorsetti M
J Cancer Res Clin Oncol; 2021 Mar; 147(3):927-936. PubMed ID: 32945972
[TBL] [Abstract][Full Text] [Related]
6. The role of albumin-bilirubin grade and inflammation-based index in patients with hepatocellular carcinoma treated with stereotactic body radiotherapy.
Gkika E; Bettinger D; Krafft L; Schultheiss M; Neeff HP; Maruschke L; Schulenburg M; Adebahr S; Kirste S; Nestle U; Thimme R; Grosu AL; Brunner TB
Strahlenther Onkol; 2018 May; 194(5):403-413. PubMed ID: 29322205
[TBL] [Abstract][Full Text] [Related]
7. Medically inoperable peripheral lung cancer treated with stereotactic body radiation therapy.
Kelley KD; Benninghoff DL; Stein JS; Li JZ; Byrnes RT; Potters L; Knisely JP; Zinkin HD
Radiat Oncol; 2015 May; 10():120. PubMed ID: 26018408
[TBL] [Abstract][Full Text] [Related]
8. Stereotactic body radiotherapy for primary hepatocellular carcinoma.
Andolino DL; Johnson CS; Maluccio M; Kwo P; Tector AJ; Zook J; Johnstone PA; Cardenes HR
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e447-53. PubMed ID: 21645977
[TBL] [Abstract][Full Text] [Related]
9. SBRT for Hepatocellular Carcinoma: 8-Year Experience from a Regional Transplant Center.
Qiu H; Moravan MJ; Milano MT; Usuki KY; Katz AW
J Gastrointest Cancer; 2018 Dec; 49(4):463-469. PubMed ID: 28710606
[TBL] [Abstract][Full Text] [Related]
10. The challenge of inoperable hepatocellular carcinoma (HCC): results of a single-institutional experience on stereotactic body radiation therapy (SBRT).
Scorsetti M; Comito T; Cozzi L; Clerici E; Tozzi A; Franzese C; Navarria P; Fogliata A; Tomatis S; D'Agostino G; Iftode C; Mancosu P; Ceriani R; Torzilli G
J Cancer Res Clin Oncol; 2015 Jul; 141(7):1301-9. PubMed ID: 25644863
[TBL] [Abstract][Full Text] [Related]
11. Stereotactic body radiation therapy in recurrent hepatocellular carcinoma.
Huang WY; Jen YM; Lee MS; Chang LP; Chen CM; Ko KH; Lin KT; Lin JC; Chao HL; Lin CS; Su YF; Fan CY; Chang YW
Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):355-61. PubMed ID: 22342300
[TBL] [Abstract][Full Text] [Related]
12. Stereotactic Body Radiotherapy for Small Unresectable Hepatocellular Carcinomas.
Yeung R; Beaton L; Rackley T; Weber B; Hamm J; Lee R; Camborde M; Pearson M; Duzenli C; Loewen SK; Liu M; Ma R; Schellenberg D
Clin Oncol (R Coll Radiol); 2019 Jun; 31(6):365-373. PubMed ID: 30792051
[TBL] [Abstract][Full Text] [Related]
13. Biologically effective dose (BED) of stereotactic body radiation therapy (SBRT) was an important factor of therapeutic efficacy in patients with hepatocellular carcinoma (≤5 cm).
Sun J; Zhang T; Wang J; Li W; Zhang A; He W; Zhang D; Li D; Ding J; Duan X
BMC Cancer; 2019 Aug; 19(1):846. PubMed ID: 31455251
[TBL] [Abstract][Full Text] [Related]
14. Stereotactic body radiation therapy (SBRT) for definitive treatment and as a bridge to liver transplantation in early stage inoperable Hepatocellular carcinoma.
Moore A; Cohen-Naftaly M; Tobar A; Kundel Y; Benjaminov O; Braun M; Issachar A; Mor E; Sarfaty M; Bragilovski D; Hur RB; Gordon N; Stemmer SM; Allen AM
Radiat Oncol; 2017 Oct; 12(1):163. PubMed ID: 29052532
[TBL] [Abstract][Full Text] [Related]
15. A phase 2 multicenter study of stereotactic body radiotherapy for hepatocellular carcinoma: Safety and efficacy.
Jang WI; Bae SH; Kim MS; Han CJ; Park SC; Kim SB; Cho EH; Choi CW; Kim KS; Hwang S; Kim JH; Chang AR; Park Y; Kim ES; Kim WC; Jo S; Park HJ
Cancer; 2020 Jan; 126(2):363-372. PubMed ID: 31747476
[TBL] [Abstract][Full Text] [Related]
16. High-dose stereotactic body radiotherapy correlates increased local control and overall survival in patients with inoperable hepatocellular carcinoma.
Jang WI; Kim MS; Bae SH; Cho CK; Yoo HJ; Seo YS; Kang JK; Kim SY; Lee DH; Han CJ; Kim J; Park SC; Kim SB; Cho EH; Kim YH
Radiat Oncol; 2013 Oct; 8():250. PubMed ID: 24160944
[TBL] [Abstract][Full Text] [Related]
17. Safety and Efficacy of Accelerated Hypofractionation and Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma Patients With Varying Degrees of Hepatic Impairment.
Nabavizadeh N; Waller JG; Fain R; Chen Y; Degnin CR; Elliott DA; Mullins BT; Patel IA; Dyer BA; Fakhoury K; Naugler WE; Farsad K; Tanyi JA; Fuss M; Thomas CR; Hung AY
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(3):577-585. PubMed ID: 29413273
[TBL] [Abstract][Full Text] [Related]
18. Stereotactic Robotic Body Radiotherapy for Patients With Unresectable Hepatic Oligorecurrence.
Berkovic P; Gulyban A; Nguyen PV; Dechambre D; Martinive P; Jansen N; Lakosi F; Janvary L; Coucke PA
Clin Colorectal Cancer; 2017 Dec; 16(4):349-357.e1. PubMed ID: 28462852
[TBL] [Abstract][Full Text] [Related]
19. Clinical feasibility and efficacy of stereotactic body radiotherapy for hepatocellular carcinoma: A systematic review and meta-analysis of observational studies.
Rim CH; Kim HJ; Seong J
Radiother Oncol; 2019 Feb; 131():135-144. PubMed ID: 30773180
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcome and pathologic correlation of stereotactic body radiation therapy as a bridge to transplantation for advanced hepatocellular carcinoma: a case series.
Wang YF; Dai YH; Lin CS; Chang HC; Shen PC; Yang JF; Hsiang CW; Lo CH; Huang WY
Radiat Oncol; 2021 Jan; 16(1):15. PubMed ID: 33446231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]